Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
06 Agosto 2024 - 5:25AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of August 2024
Commission File Number: 001-41411
Haleon plc
(Translation
of registrant’s name into English)
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
EXHIBIT INDEX
|
Exhibit
Number
|
Description
|
|
99.1
|
06
August 2024 - “Directorate
Change”
|
99.1
Haleon plc: Board Changes
6 August 2024: Haleon
plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today
announces the
appointment of two independent Non-Executive Directors to its
Board, Alan Stewart and Nancy Avila.
Alan Stewart is to be appointed as an independent Non-Executive
Director on 1 September 2024 and will join the Audit & Risk,
Environmental & Social Sustainability, Nominations &
Governance, and Remuneration Committees on appointment. Alan will
then succeed Deirdre Mahlan as the Chair of the Audit & Risk
Committee when Deirdre
steps down from the Board on 1 October 2024.
Alan has significant corporate finance, accounting and
international experience from a wide range of consumer-related
industries. He has extensive board and listed company experience.
He is currently a Non-Executive Director on the boards of Diageo
plc, where he chairs the Audit Committee and is a member of the
Remuneration and Nomination Committees, and Burberry Group plc
where he chairs the Audit Committee and is a member of the
Nomination and Remuneration Committees. He was previously
Non-Executive Director and Chair of the Remuneration Committee of
Reckitt Benckiser Group PLC. In his executive career, Alan was
Chief Financial Officer of Tesco PLC from 2014 to 2021. Prior to
joining Tesco, Alan was CFO of Marks & Spencer PLC. He is a
Chartered Accountant. Alan was a founder member of the Accounting 4
Sustainability CFO network and is currently a member of Chapter
Zero.
Nancy Avila is to be appointed as an independent Non-Executive
Director on 1 September 2024 and will join the Audit & Risk
Committee on appointment. Nancy has spent the majority of her
career in technology and business operations in healthcare, life
sciences, industrial, and distribution across several Fortune 100
companies, these include McKesson Corporation, where she was Chief
Information and Technology Officer, Johnson Controls Inc., and
Abbott Laboratories Inc. Nancy has significant experience leading
business transformations with technology, developing new digital
channels for growth, modernising operations and addressing
regulatory, technology, cyber and financial risk. Nancy is an
independent Director of Comerica Incorporated and a member of the
Enterprise Risk Committee.
Sir Dave Lewis, Haleon's Chair commented: "On behalf of the Board, I would like to welcome
Alan and Nancy to Haleon. Alan will bring a wealth of board,
executive and leadership insights and Nancy will bring valuable
technology, business transformation, digital and cyber experience
to support the Board's discussions in these areas. I would like to
thank Deirdre for her considerable contributions to the Board and
for chairing the Audit & Risk Committee since Haleon's listing
in July 2022. We wish her all the best for the
future."
The Company confirms that there is no further information to be
disclosed under the requirements of UKLR 6.4.8R in relation to Alan
Stewart's and Nancy Avila's appointments.
Amanda Mellor
Company Secretary
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with
a purpose to deliver better everyday health with humanity. Haleon's
product portfolio spans five major categories - Oral Health, Pain
Relief, Respiratory Health, Digestive Health and Other, and
Vitamins, Minerals and Supplements (VMS). Its long-standing brands
- such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin,
Polident, parodontax and Centrum - are built on trusted science,
innovation and deep human understanding.
For more information, please visit www.haleon.com.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
HALEON PLC
(Registrant)
|
|
Date: August
06, 2024
|
By:
|
/s/
Amanda Mellor
|
|
|
|
Name:
|
Amanda
Mellor
|
|
|
|
Title:
|
Company
Secretary
|
Haleon (PK) (USOTC:HLNCF)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Haleon (PK) (USOTC:HLNCF)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024
